GAM
NBIX icon

Gould Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Gould Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,400
Closed -$295K – 146
2018
Q3 		$295K Hold
2,400
– – 0.12% 106
2018
Q2 		$236K Buy
+2,400
New +$215K 0.1% 113

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gould Asset Management's NBIX Position: Q4 2018 in Review

Gould Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 2,400 shares — an estimated $295K sold.

Gould Asset Management first reported a position in NBIX in Q2 2018 and held it in 2 quarters. The position peaked at $295K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Gould Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Gould Asset Management sold 2,400 Neurocrine Biosciences shares in Q4 2018, an estimated $295K.
  • Gould Asset Management first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 2 quarters.
  • Gould Asset Management's Neurocrine Biosciences position peaked at $295K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Gould Asset Management's 13F filing for Q4 2018, filed 4 Feb 2019.